Showing results (51-60 of 62) with videos related to

Sort By:
Pageof 7
Oral Oncology|March 30, 2017
Defining an inflamed tumor immunophenotype in recurrent, metastatic squamous cell carcinoma of the head and neckGlenn J Hanna, Hongye Liu, Robert E Jones, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|January 15, 2016
Incorporation of Next-Generation Sequencing into Routine Clinical Care to Direct Treatment of Head and Neck Squamous Cell CarcinomaNicole G Chau, Yvonne Y Li, Vickie Y Jo, et al.
JAMA Oncology|October 24, 2024
Dual Immune Checkpoint Inhibition in Patients With Aggressive Thyroid Carcinoma: A Phase 2 Nonrandomized Clinical TrialKartik Sehgal, Theodora Pappa, Kee-Young Shin, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|January 6, 2018
Genomic Correlates of Response to Everolimus in Aggressive Radioiodine-refractory Thyroid Cancer: A Phase II StudyGlenn J Hanna, Naifa L Busaidy, Nicole G Chau, et al.
The New England Journal of Medicine|October 9, 2014
Response and acquired resistance to everolimus in anaplastic thyroid cancerNikhil Wagle, Brian C Grabiner, Eliezer M Van Allen, et al.
JAMA Oncology|July 31, 2015
Prognostic Implication of Persistent Human Papillomavirus Type 16 DNA Detection in Oral Rinses for Human Papillomavirus-Related Oropharyngeal CarcinomaEleni M Rettig, Alicia Wentz, Marshall R Posner, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|November 1, 2016
Genomic Heterogeneity and Exceptional Response to Dual Pathway Inhibition in Anaplastic Thyroid CancerWilliam J Gibson, Daniel T Ruan, Vera A Paulson, et al.
International Journal of Radiation Oncology, Biology, Physics|August 12, 2020
A Randomized Phase 2 Study of Pembrolizumab With or Without Radiation in Patients With Recurrent or Metastatic Adenoid Cystic CarcinomaUmair Mahmood, Andrew Bang, Yu-Hui Chen, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|October 20, 2021
Neoadjuvant and Adjuvant Nivolumab and Lirilumab in Patients with Recurrent, Resectable Squamous Cell Carcinoma of the Head and NeckGlenn J Hanna, Anne O'Neill, Kee-Young Shin, et al.
Cancer Discovery|November 5, 2017
CDK4/6 Inhibition Augments Antitumor Immunity by Enhancing T-cell ActivationJiehui Deng, Eric S Wang, Russell W Jenkins, et al.
Pageof 7